Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Less than two months after launching with $25 million in series A funding, Generation Bio has raised $100 million in series B funding to develop its re-doseable gene therapies. Existing gene therapies require DNA to be delivered into cells via a virus, which means a therapy can’t be given to the same person twice because it will cause an immune response. Generation Bio is developing a nonviral approach that uses lipid nanoparticles to deliver a strand of close-ended DNA. The Cambridge, Mass.-based firm was founded by Atlas Venture.
This article has been sent to the following recipient: